176 related articles for article (PubMed ID: 1573278)
1. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation.
Murphy WJ; Bennett M; Kumar V; Longo DL
J Immunol; 1992 May; 148(9):2953-60. PubMed ID: 1573278
[TBL] [Abstract][Full Text] [Related]
2. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
3. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
Davenport C; George T; Devora GA; Morris MA; Gordon BE; Kumar V; Bennett M
Biol Blood Marrow Transplant; 1997 Dec; 3(6):294-303. PubMed ID: 9502296
[TBL] [Abstract][Full Text] [Related]
4. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
5. Use of newborn liver cells as a murine model for cord blood cell transplantation.
Davenport C; Kumar V; Bennett M
J Immunol; 1993 Aug; 151(3):1597-605. PubMed ID: 8101544
[TBL] [Abstract][Full Text] [Related]
6. An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells.
Murphy WJ; Kumar V; Cope JC; Bennett M
J Immunol; 1990 May; 144(9):3305-11. PubMed ID: 2329274
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells activated with interleukin 2 in vitro can be adoptively transferred and mediate hematopoietic histocompatibility-1 antigen-specific bone marrow rejection in vivo.
Murphy WJ; Kumar V; Bennett M
Eur J Immunol; 1990 Aug; 20(8):1729-34. PubMed ID: 2209686
[TBL] [Abstract][Full Text] [Related]
8. [Effect of natural killer cell on hematopoiesis and immunity recovery in mouse allogeneic bone marrow transplantation].
Yang ZG; Zeng YY; He XH; Wang Q; Jiang X
Zhonghua Xue Ye Xue Za Zhi; 2004 Dec; 25(12):713-6. PubMed ID: 15730711
[TBL] [Abstract][Full Text] [Related]
9. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
[TBL] [Abstract][Full Text] [Related]
10. Activated allogeneic NK cells as suppressors of alloreactive responses.
Hu B; He Y; Wu Y; Bao G; Liu H; Welniak LA; Murphy WJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):772-81. PubMed ID: 20197103
[TBL] [Abstract][Full Text] [Related]
11. Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host.
Hummel S; Wilms D; Vitacolonna M; Zöller M
J Leukoc Biol; 2002 Nov; 72(5):898-912. PubMed ID: 12429711
[TBL] [Abstract][Full Text] [Related]
12. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
[TBL] [Abstract][Full Text] [Related]
13. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
14. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of the rejection of bone marrow allografts by the depletion of activating versus inhibiting Ly-49 natural killer cell subsets.
Raziuddin A; Longo DL; Mason L; Ortaldo JR; Bennett M; Murphy WJ
J Immunol; 1998 Jan; 160(1):87-94. PubMed ID: 9551959
[TBL] [Abstract][Full Text] [Related]
16. [Effect of activated donor-type NK cells on allogeneic bone marrow transplantation in mice].
Sun K; Zhang M; Tian Z
Zhonghua Xue Ye Xue Za Zhi; 1999 Sep; 20(9):477-9. PubMed ID: 11721413
[TBL] [Abstract][Full Text] [Related]
17. Rapid rejection of H2k and H2k/b bone marrow cell grafts by CD8+ T cells and NK cells in irradiated mice.
Davenport C; Kumar V; Bennett M
J Immunol; 1995 Oct; 155(8):3742-9. PubMed ID: 7561078
[TBL] [Abstract][Full Text] [Related]
18. Donor NK Cells and IL-15 promoted engraftment in nonmyeloablative allogeneic bone marrow transplantation.
Hu B; Bao G; Zhang Y; Lin D; Wu Y; Wu D; Liu H
J Immunol; 2012 Aug; 189(4):1661-70. PubMed ID: 22798668
[TBL] [Abstract][Full Text] [Related]
19. [Experimental study of LAK and activated NK cells affecting hematopoiesis in mice].
Sun K; Zhang M; Tian Z
Zhonghua Xue Ye Xue Za Zhi; 1999 Aug; 20(8):405-8. PubMed ID: 11721419
[TBL] [Abstract][Full Text] [Related]
20. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
